An act relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Level 5 - mechanism / opinion, no new human data
Legislative bill text; contains no empirical or clinical experimental data (graded by design analogy).
What was done
This document is a legislative bill introduced by the Texas Senate proposing the establishment of a consortium to conduct United States Food and Drug Administration (FDA) clinical drug development trials with ibogaine.
What was found
The abstract reports on proposed legislation; no empirical data, clinical trial outcomes, or numerical findings are reported.
Why it matters
It documents state legislative initiatives aiming to fund and organize clinical trials toward potential FDA approval for ibogaine in opioid use disorder and other mental health conditions.
Limits
This is a policy/legislative record, not an empirical or clinical study. It provides no evidence regarding the efficacy, safety, dosing, or therapeutic outcomes of ibogaine.
Cited by
- context The state of Texas allocated $50 million in funding for ibogaine research.